Abrocitinib is an oral, selective Janus kinase-1 (JAK1) inhibitor that blocks signalling of inflammatory cytokines involved in atopic dermatitis and related dermatoses (1). Administered once daily, it offers convenient oral therapy for adults and adolescents with moderate-to-severe disease who are unresponsive to topical or biologic agents (2). Cli
164 Reached
Woman presented with Fever of Unknown Origin
7731 Reached93 Comments19 Likes
How Physicians Should Manage Stress?
35339 Reached151 Comments202 Likes
Rubella Syndrome in Neonate
1401 Reached12 Comments9 Likes
Black Lesion in Old Female
1974 Reached5 Comments11 Likes
Chronic Hyperplastic Candidiasis Of The Oral Mucosa
858 Reached9 Comments11 Likes